Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease
Charles Andy Schuetz,1 Siew Hwa Ong,2 Matthias Blüher3 1Evidera Inc., Bethesda, MD, USA; 2Novartis Pharma AG, Basel, Switzerland; 3Department of Medicine, University of Leipzig, Leipzig, Germany Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral antidiabetic agents...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-06-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Online Access: | http://www.dovepress.com/clinical-trial-simulation-methods-for-estimating-the-impact-of-dpp-4-i-peer-reviewed-article-CEOR |